The Latest Breaking News from Gardasil

US senators are questioning Health Secretary Robert F. Kennedy Jr.'s explanation regarding his financial stake. His recent statements conflict with earlier testimony and ethics filings about Gardasil vaccine litigation. Kennedy previously stated he would transfer his interest in potential Gardasil fees to his son. However, he now claims neither he…

What the HPV vaccine actually does inside the bodyThe vaccine does not treat an existing infection. It trains the immune system to recognise and destroy the human papillomavirus before it can establish itself. Two strains, HPV 16 and HPV 18, cause roughly 70 percent of all cervical cancer cases globally.…

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

President-elect Donald Trump's pick to lead HHS has a long history of discounting and peddling misinformation about the HPV vaccine.

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products.  Pharmaceutical sales growth, excluding Lagevrio sales, was…